“Michael is an excellent addition to the CureVac board. His global financial and audit experience will help manage financial stability as we move towards late-stage clinical development and commercialization,” said Jean Stéphenne, Chairman of CureVac’s Supervisory Board. “We would like to extend our wholehearted thanks to Hans Christoph for his dedication and guidance for the past eight years and wish him the very best for the future.”

Mr. Brosnan is a highly regarded international financial expert, with extensive experience in executive and non-executive financial board roles and as an auditor. He currently serves as a member of the supervisory board and chairman of the audit committee at MorphoSys AG. He also is a member of the supervisory board and chairman of the audit Committee of Daimler Truck AG. Until his retirement in 2019, he was the CFO of Fresenius Medical Care Management AG. Prior to taking over management roles in financial departments, he was an audit partner at KPMG. Mr. Brosnan holds a degree in business administration and accounting from North­eastern University, Boston.

“CureVac is a pioneer in the mRNA field, and I’m delighted to join the company at a time of exceptional growth and progress,” said Mr. Brosnan. “I look forward to working with my fellow Supervisory Board members and the executive team to help deliver on the promise of this transformative technology.”